NCT04319354View on ClinicalTrials.gov

Evaluation of cfDNA as a Marker of Response in Rectal Cancer

NACompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

November 18, 2019

Primary Completion Date

April 30, 2021

Study Completion Date

December 30, 2021

Conditions
Cancer of Rectum
Interventions
DIAGNOSTIC_TEST

Analysis of cfDNA

Analysis of cfDNA through liquid biopsy

Trial Locations (1)

4464-513

Hospital Pedro Hispano, Matosinhos Municipality

All Listed Sponsors
collaborator

Diogo Melo Pinto, MD, Hospital Pedro Hispano

UNKNOWN

collaborator

Telma Fonseca, MD, Centro Hospitalar de São João

UNKNOWN

collaborator

Silvestre Carneiro, PhD, Centro Hospitalar de São João

UNKNOWN

collaborator

Isabel Prieto, PhD, Hospital La Paz, Madrid

UNKNOWN

lead

Hospital Pedro Hispano

OTHER

NCT04319354 - Evaluation of cfDNA as a Marker of Response in Rectal Cancer | Biotech Hunter | Biotech Hunter